Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19

被引：0

作者：

Shohei Eto

Yoko Nukui

Miyuki Tsumura

Yu Nakagama

Kenichi Kashimada

Yoko Mizoguchi

Takanori Utsumi

Maki Taniguchi

Fumiaki Sakura

Kosuke Noma

Yusuke Yoshida

Shinichiro Ohshimo

Shintaro Nagashima

Keisuke Okamoto

Akifumi Endo

Kohsuke Imai

Hirokazu Kanegane

Hidenori Ohnishi

Shintaro Hirata

Eiji Sugiyama

Nobuaki Shime

Masanori Ito

Hiroki Ohge

Yasutoshi Kido

Paul Bastard

Jean-Laurent Casanova

Osamu Ohara

Junko Tanaka

Tomohiro Morio

Satoshi Okada

机构：

[1] Hiroshima University Graduate School of Biomedical and Health Science,Department of Pediatrics

[2] Tokyo Medical and Dental University Hospital,Department of Infection Control and Prevention

[3] Kyoto Prefectural University of Medicine,Department of Infection Control and Laboratory Medicine

[4] Osaka City University,Department of Parasitology, Graduate School of Medicine

[5] Tokyo Medical and Dental University,Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences

[6] Hiroshima University Hospital,Department of Clinical Immunology and Rheumatology

[7] Hiroshima University Graduate School of Biomedical and Health Science,Department of Emergency and Critical Care Medicine

[8] Hiroshima University Graduate School of Biomedical and Health Sciences,Department of Epidemiology Infectious Disease Control and Prevention

[9] Tokyo Medical and Dental University Hospital,Clinical Research Center

[10] Tokyo Medical and Dental University,Department of Community Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences

[11] Tokyo Medical and Dental University,Department of Child Health and Development

[12] Gifu University Graduate School of Medicine,Department of Pediatrics

[13] Emeritus Professor of Hiroshima University,Department of General Internal Medicine

[14] Hiroshima University Hospital,Department of Infectious Diseases

[15] Hiroshima University Hospital,Laboratory of Human Genetics of Infectious Diseases, Necker Branch

[16] INSERM U1163,St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch

[17] Necker Hospital for Sick Children,Department of Applied Genomics

[18] University of Paris,undefined

[19] Imagine Institute,undefined

[20] The Rockefeller University,undefined

[21] Howard Hughes Medical Institute,undefined

[22] Kazusa DNA Research Institute,undefined

来源：

Journal of Clinical Immunology | 2022年 / 42卷

关键词：

COVID-19; Antibodies to type I IFNs; IFN-α2; IFN-ω; Neutralization assay; IFN-α2 concentration;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：1360 / 1370

页数：10

共 50 条

[21] Neutralizing Anti-interferon-γ Autoantibodies: an Ameliorating Factor in COVID-19 Infection?
Mark Kacar
Paulina Cortes-Acevedo
Vinesh Patel
Clive Carter
Pamela Hughes
Hugh P. McGann
Effrossyni Gkrania-Klotsas
Helen E. Baxendale
Gabriela Barcenas-Morales
Rainer Doffinger
Sinisa Savic
Journal of Clinical Immunology, 2021, 41 : 1531 - 1535
[22] Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
Angélique Chauvineau-Grenier
Paul Bastard
Jean-Laurent Casanova
Benjamin Rossi
Journal of Clinical Immunology, 2022, 42 : 1107 - 1110
[23] Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
Chauvineau-Grenier, Angelique
Bastard, Paul
Casanova, Jean-Laurent
Rossi, Benjamin
JOURNAL OF CLINICAL IMMUNOLOGY, 2022, 42 (06) : 1107 - 1110
[24] High frequency of neutralizing antibodies to type I Interferon in HIV-1 patients hospitalized for COVID-19
Scordio, Mirko
Frasca, Federica
Santinelli, Letizia
Sorrentino, Leonardo
Pierangeli, Alessandra
Turriziani, Ombretta
Mastroianni, Claudio M.
Antonelli, Guido
Viscidi, Raphael P.
d'Ettorre, Gabriella
Scagnolari, Carolina
CLINICAL IMMUNOLOGY, 2022, 241
[25] Low type I interferon response in COVID-19 patients: Interferon response may be a potential treatment for COVID-19
Salman, Ahmed Abdulwahid
Waheed, Mohammed Hussein
Abd Ali-Abdulsahib, Akeel
Atwan, Zeenah Weheed
BIOMEDICAL REPORTS, 2021, 14 (05)
[26] Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients
Goncalves, David
Mezidi, Mehdi
Bastard, Paul
Perret, Magali
Saker, Kahina
Fabien, Nicole
Pescarmona, Remi
Lombard, Christine
Walzer, Thierry
Casanova, Jean-Laurent
Belot, Alexandre
Richard, Jean-Christophe
Trouillet-Assant, Sophie
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2021, 10 (08)
[27] Critically ill COVID-19 patients with neutralizing autoantibodies against type I interferons have increased risk of herpesvirus disease
Busnadiego, Idoia
Abela, Irene A.
Frey, Pascal M.
Hofmaenner, Daniel A.
Scheier, Thomas C.
Schuepbach, Reto A.
Buehler, Philipp K.
Brugger, Silvio D.
Hale, Benjamin G.
PLOS BIOLOGY, 2022, 20 (07)
[28] Increased blood immune regulatory cells in severe COVID-19 with autoantibodies to type I interferons
Fatemeh Saheb Sharif-Askari
Narjes Saheb Sharif-Askari
Shirin Hafezi
Hawra Ali Hussain Alsayed
Balachandar Selvakumar
Mariam Wed Abdelaziz Eladham
Bushra Mdkhana
Ola Salam Bayram
Mohamad-Hani Temsah
Rabih Halwani
Scientific Reports, 13
[29] Increased blood immune regulatory cells in severe COVID-19 with autoantibodies to type I interferons
Sharif-Askari, Fatemeh Saheb
Sharif-Askari, Narjes Saheb
Hafezi, Shirin
Alsayed, Hawra Ali Hussain
Selvakumar, Balachandar
Eladham, Mariam Wed Abdelaziz
Mdkhana, Bushra
Bayram, Ola Salam
Temsah, Mohamad-Hani
Halwani, Rabih
SCIENTIFIC REPORTS, 2023, 13 (01)
[30] Dysregulation of type I interferon responses in COVID-19
Dhiraj Acharya
GuanQun Liu
Michaela U. Gack
Nature Reviews Immunology, 2020, 20 : 397 - 398

← 1 2 3 4 5 →